EpimAb Biotherapeutics

company

About

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.

  • Shanghai,Shanghai,China
  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$120M
Industries
Biopharma,Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.

Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$219M
EpimAb Biotherapeutics has raised a total of $219M in funding over 2 rounds. Their latest funding was raised on Mar 22, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 22, 2021 Series C $120M 12 MiraeAsset Financial Group
CMB International Capital Corporation
Detail
Jun 5, 2019 Series B $74M 3 SDIC Fund Management
Sherpa Venture Capital
Detail
Apr 24, 2017 Series A $25M 4 Oriza Seed Capital (Oriza Yuandian) Detail

Employee Profiles

Number of Employee Profiles
8
EpimAb Biotherapeutics has 8 current employee profiles, including Board member Cheng Xing
Board member
Executive
Board member
Executive
Executive